Shanghai InnoStar Bio-tech Co (SHSE:688710) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688710 Shanghai InnoStar Bio-tech Co Ltd SHSE:688710
37 GF Score
Price ¥91.57
! 6 Warning Signs
View Full Analysis

What is Shanghai InnoStar Bio-tech Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shanghai InnoStar Bio-tech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ¥15.9 Mil. Shanghai InnoStar Bio-tech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ¥114.4 Mil. Shanghai InnoStar Bio-tech Co's annualized EBITDA for the quarter that ended in Jun. 2026 was ¥219.8 Mil. Shanghai InnoStar Bio-tech Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Shanghai InnoStar Bio-tech Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:688710' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.76   Med: 1.1   Max: 4.07
Current: 4.07

During the past 7 years, the highest Debt-to-EBITDA Ratio of Shanghai InnoStar Bio-tech Co was 4.07. The lowest was 0.76. And the median was 1.10.

SHSE:688710's Debt-to-EBITDA is ranked worse than
76.37% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs SHSE:688710: 4.07

Shanghai InnoStar Bio-tech Co  (SHSE:688710) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Shanghai InnoStar Bio-tech Co Debt-to-EBITDA Related Terms

Shanghai InnoStar Bio-tech Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Shanghai InnoStar Bio-tech Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai InnoStar Bio-tech Co Debt-to-EBITDA Chart

Shanghai InnoStar Bio-tech Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

Shanghai InnoStar Bio-tech Co Quarterly Data
Sep23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SHSE:688710 vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison

For the Drug Manufacturers - General subindustry, Shanghai InnoStar Bio-tech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai InnoStar Bio-tech Co Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai InnoStar Bio-tech Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shanghai InnoStar Bio-tech Co's Debt-to-EBITDA falls into.


SHSE:688710
37GF Score
Shanghai InnoStar Bio-tech Co Ltd SHSE:688710
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai InnoStar Bio-tech Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shanghai InnoStar Bio-tech Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11.09395727 + 104.59033695) / 88.33209144
=1.31

Shanghai InnoStar Bio-tech Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.87014501 + 114.38801019) / 219.75620892
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Shanghai InnoStar Bio-tech Co Business Description

Address No. 199 Guo Shoujing Road, Room 106, Pilot Free Trade Zone, Shanghai, CHN, 201203
Shanghai InnoStar Bio-tech Co Ltd is a comprehensive research and development services (CRO) enterprise that specializes in providing biomedical non-clinical research services.
37GF Score

Get the complete analysis for SHSE:688710

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥91.57
Price